新冠住院患者继续与停用肾素-血管紧张素系统抑制剂:前瞻性随机开放标签试验
REPLACE COVID试验在7国20家医院纳入152例住院前已服用肾素-血管紧张素系统抑制剂的COVID-19住院患者,随机分为继续或停用组。主要终点全球排名评分两组无差异(β系数8,95%CI -13至29),继续用药安全性良好,支持住院期间可安全继续使用。
要点
- COVID-19住院患者继续使用RAS抑制剂未改善全球排名评分(β系数8,95%CI -13至29)。
- 继续组与停用组ICU入住或有创通气率分别为21%与18%,病死率分别为15%与13%。
- 两组不良事件、血压、血钾及肌酐随访期间无差异,支持安全继续用药。
核心结论
- 与国际学会推荐一致,COVID-19住院患者可安全继续使用肾素-血管紧张素系统抑制剂。
研究设计与样本
- REPLACE COVID为前瞻性、随机、开放标签试验,在7国20家大型转诊医院开展。
- 纳入152例年龄≥18岁、住院前已服用RAS抑制剂的COVID-19住院患者,1:1随机分为继续组(n=75)与停用组(n=77)。
主要发现
- 主要终点全球排名评分两组无差异:继续组中位排名73(IQR 40-110),停用组81(IQR 38-117),β系数8(95%CI -13至29)。
- 继续组16例(21%)、停用组14例(18%)需要ICU入住或有创机械通气;继续组11例(15%)、停用组10例(13%)死亡。
- 随访期间两组血压、血清钾或肌酐无差异。
临床怎么用
- 对住院前已服用RAS抑制剂的COVID-19住院患者,可考虑继续用药而非停用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biological considerations suggest that renin-angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) affects outcomes in patients admitted to hospital with COVID-19. METHODS: The REPLACE COVID trial was a prospective, randomised, open-label trial done at 20 large referral hospitals in seven countries worldwide. Eligible participants were aged 18 years and older who were admitted to hospital with COVID-19 and were receiving a renin-angiotensin system inhibitor before admission. Individuals with contraindications to continuation or discontinuation of renin-angiotensin system inhibitor therapy were excluded. Participants were randomly assigned (1:1) to continuation or discontinuation of their renin-angiotensin system inhibitor using permuted block randomisation, with allocation concealed using a secure web-based randomisation system. The primary outcome was a global rank score in which participants were ranked across four hierarchical tiers incorporating time to death, duration of mechanical ventilation, time on renal replacement or vasopressor therapy, and multiorgan dysfunction during the hospitalisation. Primary analyses were done in the intention-to-treat population. The REPLACE COVID trial is registered with ClinicalTrials.gov, NCT04338009. FINDINGS: Between March 31 and Aug 20, 2020, 152 participants were enrolled and randomly assigned to either continue or discontinue renin-angiotensin system inhibitor therapy (continuation group n=75; discontinuation group n=77). Mean age of participants was 62 years (SD 12), 68 (45%) were female, mean body-mass index was 33 kg/m2 (SD 8), and 79 (52%) had diabetes. Compared with discontinuation of renin-angiotensin system inhibitors, continuation had no effect on the global rank score (median rank 73 [IQR 40-110] for continuation vs 81 [38-117] for discontinuation; β-coefficient 8 [95% CI -13 to 29]). There were 16 (21%) of 75 participants in the continuation arm versus 14 (18%) of 77 in the discontinuation arm who required intensive care unit admission or invasive mechanical ventilation, and 11 (15%) of 75 participants in the continuation group versus ten (13%) of 77 in the discontinuation group died. 29 (39%) participants in the continuation group and 28 (36%) participants in the discontinuation group had at least one adverse event (χ2 test of adverse events between treatment groups p=0·77). There was no difference in blood pressure, serum potassium, or creatinine during follow-up across the two groups. INTERPRETATION: Consistent with international society recommendations, renin-angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19. FUNDING: REPLACE COVID Investigators, REPLACE COVID Trial Social Fundraising Campaign, and FastGrants.
引用
- Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021. PMID: 33422263. doi:10.1016/S2213-2600(20)30558-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。